Genprex, Inc. (LON:0A8I)
London
· Delayed Price · Currency is GBP · Price in USD 0.400
-0.000 (-0.03%)
At close: Feb 20, 2025
Genprex Employees
Genprex had 26 employees as of December 31, 2023. The number of employees decreased by 2 or -7.14% compared to the previous year.
Employees
26
Change (1Y)
-2
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-891.78K GBP
Market Cap
2.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 89,900 |
| Shell | 103,000 |
| HSBC Holdings | 220,861 |
| Unilever | 128,377 |
| Rio Tinto Group | 57,000 |
| RELX PLC | 36,400 |
| BP p.l.c. | 87,800 |
| British American Tobacco p.l.c. | 48,989 |
Genprex News
- 10 days ago - Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - PRNewsWire
- 4 weeks ago - Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PRNewsWire
- 6 weeks ago - Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer - PRNewsWire
- 3 months ago - Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer - PRNewsWire
- 3 months ago - Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - PRNewsWire
- 4 months ago - Genprex to Participate in 2024 BIO Europe Conference - PRNewsWire
- 4 months ago - Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma - PRNewsWire